“Long-Term Improvements in Health-Related Quality of Life of Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Results from the CIMPASI-1 and CIMPASI-2 Phase 3 Trials” (2021) SKIN The Journal of Cutaneous Medicine, 5(1), p. s20. doi:10.25251/skin.5.supp.20.